Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 3
2007 2
2008 4
2009 1
2010 1
2012 1
2014 1
2017 1
2018 1
2019 1
2021 3
2022 5
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacological targeting of glutamatergic neurons within the brainstem for weight reduction.
Schneeberger M, Brice NL, Pellegrino K, Parolari L, Shaked JT, Page KJ, Marchildon F, Barrows DW, Carroll TS, Topilko T, Mulligan VM, Newman R, Doyle K, Bürli R, Barker DF, Glen A, Ortuño MJ, Nectow AR, Renier N, Cohen P, Carlton M, Heintz N, Friedman JM. Schneeberger M, et al. Among authors: carlton m. Nat Metab. 2022 Nov;4(11):1495-1513. doi: 10.1038/s42255-022-00677-8. Epub 2022 Nov 21. Nat Metab. 2022. PMID: 36411386 Free PMC article.
Discovery and Characterization of Novel CNS-Penetrant GPR55 Agonists.
Hewer RC, Christie LA, Doyle KJ, Xu X, Roberts MJ, Dickson L, Cheung T, Cadwalladr DH, Pickford P, Teall M, Powell JAC, Sheardown S, Narayana L, Brice NL, Dawson LA, Carlton M, Bürli RW. Hewer RC, et al. Among authors: carlton m. J Med Chem. 2023 Sep 28;66(18):12858-12876. doi: 10.1021/acs.jmedchem.3c00784. Epub 2023 Sep 14. J Med Chem. 2023. PMID: 37708305
Characterisation of C101248: A novel selective THIK-1 channel inhibitor for the modulation of microglial NLRP3-inflammasome.
Ossola B, Rifat A, Rowland A, Hunter H, Drinkall S, Bender C, Hamlischer M, Teall M, Burley R, Barker DF, Cadwalladr D, Dickson L, Lawrence JMK, Harvey JRM, Lizio M, Xu X, Kavanagh E, Cheung T, Sheardown S, Lawrence CB, Harte M, Brough D, Madry C, Matthews K, Doyle K, Page K, Powell J, Brice NL, Bürli RW, Carlton MB, Dawson LA. Ossola B, et al. Among authors: carlton mb. Neuropharmacology. 2023 Feb 15;224:109330. doi: 10.1016/j.neuropharm.2022.109330. Epub 2022 Nov 12. Neuropharmacology. 2023. PMID: 36375694 Free PMC article.
Luvadaxistat: A Novel Potent and Selective D-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia.
Fradley R, Goetghebeur P, Miller D, Burley R, Almond S, Gruart I Massó A, Delgado García JM, Zhu B, Howley E, Neill JC, Grayson B, Gaskin P, Carlton M, Gray I, Serrats J, Davies CH. Fradley R, et al. Among authors: carlton m. Neurochem Res. 2023 Oct;48(10):3027-3041. doi: 10.1007/s11064-023-03956-2. Epub 2023 Jun 8. Neurochem Res. 2023. PMID: 37289348 Free PMC article.
Synthesis and SAR of novel GPR39 agonists and positive allosteric modulators.
Burley R, Hewer RC, Teall M, Dickson L, Ossola B, Russell S, Bender C, Cheung T, Powell JAC, Xu X, Brice NL, Otter L, Arimont M, Kidd SL, Vidal D, Dale JW, Mervin L, Sore HF, Mateu N, Lakshminarayana N, Dawson LA, Carlton M, Bürli RW. Burley R, et al. Among authors: carlton m. Bioorg Med Chem Lett. 2022 Apr 1;61:128607. doi: 10.1016/j.bmcl.2022.128607. Epub 2022 Feb 3. Bioorg Med Chem Lett. 2022. PMID: 35123006
Discovery of CVN417, a Novel Brain-Penetrant α6-Containing Nicotinic Receptor Antagonist for the Modulation of Motor Dysfunction.
Christie LA, Brice NL, Rowland A, Dickson L, Anand R, Teall M, Doyle KJ, Narayana L, Mitchell C, Harvey JRM, Mulligan V, Dawson LA, Cragg SJ, Carlton M, Bürli RW. Christie LA, et al. Among authors: carlton m. J Med Chem. 2023 Sep 14;66(17):11718-11731. doi: 10.1021/acs.jmedchem.3c00630. Epub 2023 Aug 31. J Med Chem. 2023. PMID: 37651656
Insulin-like peptide 5 is an orexigenic gastrointestinal hormone.
Grosse J, Heffron H, Burling K, Akhter Hossain M, Habib AM, Rogers GJ, Richards P, Larder R, Rimmington D, Adriaenssens AA, Parton L, Powell J, Binda M, Colledge WH, Doran J, Toyoda Y, Wade JD, Aparicio S, Carlton MB, Coll AP, Reimann F, O'Rahilly S, Gribble FM. Grosse J, et al. Among authors: carlton mb. Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11133-8. doi: 10.1073/pnas.1411413111. Epub 2014 Jul 15. Proc Natl Acad Sci U S A. 2014. PMID: 25028498 Free PMC article. Clinical Trial.
Discovery of CVN636: A Highly Potent, Selective, and CNS Penetrant mGluR7 Allosteric Agonist.
Dickson L, Teall M, Chevalier E, Cheung T, Liwicki GM, Mack S, Stephenson A, White K, Fosbeary R, Harrison DC, Brice NL, Doyle K, Ciccocioppo R, Wu C, Almond S, Patel TR, Mitchell P, Barnes M, Ayscough AP, Dawson LA, Carlton M, Bürli RW. Dickson L, et al. Among authors: carlton m. ACS Med Chem Lett. 2023 Mar 2;14(4):442-449. doi: 10.1021/acsmedchemlett.2c00529. eCollection 2023 Apr 13. ACS Med Chem Lett. 2023. PMID: 37077399 Free PMC article.
A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson's Disease.
Margolin DH, Brice NL, Davidson AM, Matthews KL, Carlton MBL. Margolin DH, et al. Among authors: carlton mbl. J Pharmacol Exp Ther. 2022 Apr;381(1):33-41. doi: 10.1124/jpet.121.000842. Epub 2022 Feb 2. J Pharmacol Exp Ther. 2022. PMID: 35110393 Clinical Trial.
Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.
Sehatpour P, Javitt DC, De Baun HM, Carlson M, Beloborodova A, Margolin DH, Carlton MBL, Brice NL, Kantrowitz JT. Sehatpour P, et al. Among authors: carlton mbl. Neuropsychopharmacology. 2022 Feb;47(3):711-718. doi: 10.1038/s41386-021-01170-8. Epub 2021 Oct 20. Neuropsychopharmacology. 2022. PMID: 34667294 Free PMC article. Clinical Trial.
34 results